OUR GOAL IS TO BE A LEADER IN THE DEVELOPEMENT OF TARGETED THERAPIES FOR PATIENTS WITH CANCER AND OTHER DISEASES OF HIGH UNMET NEED
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration (“AMD”) and fibrotic diseases. Our lead product candidate, DE-122, is an endoglin antibody that is being developed for the treatment of wet AMD in the randomized Phase 2 AVANTE trial through a collaboration with Santen Pharmaceutical Co., Ltd., a global ophthalmology company who licensed from us exclusive worldwide rights to develop and commercialize our endoglin antibodies for ophthalmology indications. Our other product candidates are TRC102, a small molecule that is in Phase 2 clinical development for the treatment of mesothelioma; TRC253, an small molecule inhibitor of wild type and mutated forms of the androgen receptor that is in Phase 2 clinical development for prostate cancer, that is being developed through a collaboration with Janssen Pharmaceutica N.V.; TJ004309, a CD73 antibody that is expected to begin Phase 1 testing in 2019, that is being developed through a collaboration with I-Mab Biopharma; multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma; and TRC205, an endoglin antibody that is in preclinical development for the treatment of fibrotic diseases.
We operate a clinical development model that emphasizes capital efficiency. Our experienced clinical operations, product development and regulatory affairs groups enable us to eliminate the cost associated with hiring contract research organizations to manage clinical, regulatory and database aspects of our Phase 1, Phase 2 and Phase 3 clinical trials. We have also collaborated with the National Cancer Institute, which selected TRC102 for federal funding of clinical development, as well as Case Western Reserve University.